OMedLive

Industry Speakers

 

  • Ralph V. Boccia, MD, FACP

    Ralph V. Boccia, MD, FACP

    Ralph V. Boccia, MD, FACP

    Ralph V. Boccia, MD, FACP, is Medical Director of the Center for Cancer and Blood Disorders in Bethesda, Maryland, and Clinical Associate Professor of Medicine at Georgetown University in Washington. He serves as the Chief Medical Officer for the International Oncology Network (ION). Dr. Boccia completed a residency in Internal Medicine at the University of California, Los Angeles (UCLA). He then did a fellowship in Hematology/Oncology, and Bone Marrow Transplant at UCLA and the West Los Angeles VA Medical Center, and was then recruited to the Medicine Branch at the National Institutes of Health’s National Cancer Center in Bethesda.

    Dr. Boccia is a Fellow of the American College of Physicians(ACP) and a member of the American Society of Clinical Oncology(ASCO), American Society of Hematology(ASH), and Multinational Association for Supportive Care in Cancer(MASCC). He is on the Editorial Board for the Journal of Hematology & Oncology and Oncology and Biotech News. Dr. Boccia has authored or coauthored numerous articles published in such peer-reviewed journals as the Journal of Clinical Oncology, British Journal of Haematology, New England Journal of Medicine, Cancer, Oncologist, Blood, and Clinical Colorectal Cancer, amongst others. He has been voted to Top Doctors in America, and Best Doctors in Washington, DC since 2002.
  • John A. Glaspy, MD, MPH, FACP

    John A. Glaspy, MD, MPH, FACP

    John A. Glaspy, MD, MPH, FACP

    John Glaspy, MD, MPH, is professor of medicine at the Jonsson Comprehensive Cancer Center (JCCC) of the University of California, Los Angeles (UCLA) School of Medicine. Dr. Glaspy holds the Estelle, Abe, and Marjorie Sanders Endowed Chair in Cancer Research. He is director of the JCCC Clinical Research Unit and director of the JCCC Women's Cancer Research Program.

    Dr. Glaspy is a member of the American Society of Clinical Oncology, Southwest Oncology Group, American Federation for Clinical Research, International Society of Interferon Research, and American Society of Nuclear Medicine, among others. He is also a fellow of the American College of Physicians. During the course of his career, Dr. Glaspy has authored more than 270 articles, abstracts, and book chapters. He has received numerous awards and honors, including being named one of the "Best Doctors in America."

    Currently, Dr. Glaspy is involved in basic research in tumor immunology and the effects of fatty acids on carcinogenesis. His clinical interests also include chemotherapy-induced anemia, the role of hematopoietic growth factors in cancer management, and new approaches to the treatment of breast cancer and malignant melanoma. Dr. Glaspy received his MD from the UCLA School of Medicine and his MPH in health services administration from the UCLA School of Public Health. He completed his residency in internal medicine and his fellowship in hematology and oncology at the UCLA School of Medicine.
  • Daniel J. George, MD

    Daniel J. George, MD

    Daniel J. George, MD

    Medical Oncologist, Director of GU Oncology Duke Cancer Institute

    Dr Daniel George is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. He is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 150 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and angiogenesis. Dr. George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006, specializing in Phase I and II studies in prostate cancer. He is also the PI of the MaRCC registry in advanced renal cell carcinoma and Co-PI of IRONMAN, an international, multi-sponsor supported registry in advanced prostate cancer. Dr. George serves on the ASCO scientific committee for non-prostate cancer, the Alliance GU scientific committee, NCI GU Steering Committee and the NCI Renal Task Force. He also serves as a senior editor for Clinical Cancer Research and Clinical Advances in Hematology and Oncology.
  • Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Medical Director

    Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.

    Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, Society of Urologic Oncology Clinical Trials Consortium, Secretary-Treasurer, and is President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 125 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.

    A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
  • Noopur Raje, MD

    Noopur Raje, MD

    Noopur Raje, MD

    Dr. Noopur Raje is a physician scientist with a focus on the development of innovative therapies for multiple myeloma. As Director of the Center for Multiple Myeloma at the Massachusetts General Hospital (MGH) Cancer Center, Dr. Raje leads a dedicated clinical team engaged in investigator-initiated, multicenter national and international clinical trials, all aimed at developing new promising therapies for this disease. She also leads translational efforts at MGH with her laboratory’s efforts focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and whose targeting may result in improved therapeutic outcomes. Dr. Raje received her medical degree from B.J. Medical College, Pune University in India, trained in Internal Medicine at MGH and subsequently completed a fellowship in hematology and medical oncology in the joint Mass General-Brigham & Women’s-Dana-Farber program. She is an Associate Professor of Medicine at Harvard Medical School and the Rita M. Kelley Chair in Oncology at Massachusetts General Hospital. She is the recipient of numerous awards including the Multiple Myeloma Senior Research Award, The Leukemia and Lymphoma Society Clinical Scholar Award and the Claflin Distinguished Scholar Award.